深圳市儿童医院9月22日在2026深圳医工融合创新发展交流会上展示了三项儿科创新成果1。这些成果分别为超声刀腔镜手术安全装置、重组黏液溶解蛋白雾化药物和儿童专用中成药，针对儿科手术、呼吸道疾病和中医药短缺等临床痛点1。医院与10家单位完成签约，建立联合攻关机制1。
超声刀新型组件已解决线缆黏性晃动问题，获得专利授权，完成样机验证1。重组黏液溶解蛋白药物体外实验显示痰液黏弹性下降60%以上，目前处于临床前候选药物阶段1。
深圳市儿童医院累计承接临床试验281项，其中20余项临床试验成果成功获批上市1。
Shenzhen Children's Hospital unveiled three significant pediatric innovations at the 2026 Shenzhen Medical-Engineering Integration Innovation Development Forum on September 22 1. The three developments—an ultrasonic scalpel laparoscopic surgery safety device, recombinant mucus-dissolving protein nebulized medication, and a pediatric-specific Chinese medicine formulation—each address distinct clinical challenges in pediatric care 1.
The ultrasonic scalpel innovation has overcome cable adhesion and vibration issues through a new component design, having secured patent authorization and completed prototype validation 1. The recombinant mucus-dissolving protein medication demonstrated in vitro results showing a 60 percent or greater reduction in sputum viscoelasticity and is currently at the preclinical candidate drug stage 1. These innovations represent different stages of development across surgical, respiratory, and traditional Chinese medicine applications 1.
As part of the forum activities, the hospital formalized collaborative partnerships by signing agreements with 10 partner organizations to establish joint research mechanisms 1. The hospital has cumulatively undertaken 281 clinical trials, with over 20 trial outcomes successfully receiving market approval 1.
评论
还没有评论，欢迎留下第一条。